Envista Holdings Dirección

Dirección controles de criterios 2/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

Paul Keel

Chief Executive Officer (CEO)

n/a

Compensación total

Porcentaje del salario del CEO	n/a
Permanencia del CEO	no data
Participación del CEO	n/a
Permanencia media de la dirección	2.6yrs
Promedio de permanencia en la Junta Directiva	4.5yrs

Actualizaciones recientes de la dirección

Recent updates

CEO

Paul Keel (53 yo)

no data

Permanencia

Mr. Paul A. Keel serves as CEO & Director of Envista Holdings since May 1, 2024. He served as Chief Executive Officer and Executive Director at Smiths Group plc since May 25, 2021 until March 26, 2024. He...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Stephen Keller	VP of Investor Relations & Principal Financial Officer	3.2yrs	US$703.93k	0.0040% $ 120.5k
Mark Nance	Senior VP	4.7yrs	US$1.54m	0.016% $ 471.8k
Eric Conley	Senior VP & President of Orthodontics	4.3yrs	US$2.12m	0.012% $ 353.8k
Paul Keel	CEO & Director	no data	sin datos	sin datos
Faez Kaabi	VP, Chief Accounting Officer & Corporate Controller	4.7yrs	sin datos	0.0059% $ 178.6k
Andrew Chen	Chief Information Officer	less than a year	sin datos	sin datos
Paul Sumilas	Chief Compliance Officer	less than a year	sin datos	sin datos
Mischa Reis	Senior Vice President of Strategy & Corporate Development	4.7yrs	sin datos	0.025% $ 770.5k
Suraj Satpathy	Chief Human Resources officer	less than a year	sin datos	sin datos
Filippo Impieri	Senior Vice President of Emerging Markets	no data	sin datos	sin datos
Claudia Ortiz	Senior Vice President of Regulatory Affairs & Quality Assurance	no data	sin datos	sin datos
David Armstrong	President of Restorative & Endodontics	2.1yrs	sin datos	sin datos

2.6yrs

Permanencia media

53yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de 0HV se considera experimentado (3.7 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Paul Keel	CEO & Director	no data	sin datos	sin datos
Daniel Raskas	Independent Director	5.3yrs	US$285.05k	0% $ 0
Christine Tsingos	Independent Director	4.7yrs	US$310.05k	0% $ 0
Kieran Gallahue	Independent Director	4.4yrs	US$300.05k	0% $ 0
Barbara Hulit	Independent Director	2.4yrs	US$285.05k	0.0040% $ 121.4k
R. Huennekens	Independent Chairman of the Board	4.7yrs	US$435.09k	0% $ 0
Vivek Jain	Independent Director	4.1yrs	US$285.05k	0% $ 0
Wendy Carruthers	Independent Director	4.7yrs	US$305.05k	0.000010% $ 304.2

4.5yrs

Permanencia media

56yo

Promedio de edad

Junta con experiencia: La junta directiva de 0HV se considera experimentada (4.6 años de antigüedad promedio).

Envista Holdings Dirección

Dirección controles de criterios 2/4

Información clave

Actualizaciones recientes de la dirección

Envista Holdings Corporation Announces Chief Executive Officer Changes

Envista Holdings Corporation, Annual General Meeting, May 21, 2024

Insufficient new directors

Insufficient new directors

Envista Holdings Corporation Appoints Three New Members to Leadership Team

Insufficient new directors

Recent updates

First quarter 2024 earnings released: EPS: US$0.14 (vs US$0.27 in 1Q 2023)

Envista Holdings Corporation Announces Chief Executive Officer Changes

Envista Holdings Corporation, Annual General Meeting, May 21, 2024

Envista Holdings Corporation to Report Q1, 2024 Results on May 01, 2024

Insufficient new directors

Full year 2023 earnings released: US$0.60 loss per share (vs US$1.46 profit in FY 2022)

Insufficient new directors

Envista Holdings Corporation Provides Earnings Guidance for the Full Year 2024

Envista Holdings Corporation to Report Q4, 2023 Results on Feb 07, 2024

Envista Holdings Corporation Appoints Three New Members to Leadership Team

Insufficient new directors

New minor risk - Shareholder dilution

Third quarter 2023 earnings released: EPS: US$0.13 (vs US$0.30 in 3Q 2022)

Envista Holdings Corporation Provides Earnings Guidance for the Year 2023

Envista Holdings Corporation to Report Q3, 2023 Results on Nov 01, 2023

Insufficient new directors

Envista Holdings Corporation to Report Q2, 2023 Results on Aug 02, 2023

Insufficient new directors

Investor sentiment deteriorates as stock falls 16%

Envista Holdings Corporation Provides Earnings Guidance for the Year 2023

Envista Holdings Corporation to Report Q4, 2022 Results on Feb 08, 2023

Envista Holdings Corporation Provides Earnings Guidance for the Year 2022

Envista Holdings Corporation to Report Q3, 2022 Results on Nov 03, 2022

High number of new directors

Second quarter 2022 earnings released: EPS: US$0.27 (vs US$0.49 in 2Q 2021)

Envista Holdings Corporation Provides Sales Guidance for 2022

Envista Holdings Corporation Provides Sales Guidance for 2022

Envista Holdings Corporation to Report Q2, 2022 Results on Aug 03, 2022

Investor sentiment deteriorated over the past week

Envista Holdings Corporation (NYSE : NVST) agreed to acquire Osteogenics Biomedical, Inc., Allotech, LLC and OBI Biologics, Inc.

First quarter 2022 earnings released: EPS: US$0.43 (vs US$0.39 in 1Q 2021)

Envista Holdings Corporation Provides Unaudited Consolidated Impairment Charges for the First Quarter Ended April 1, 2022

High number of new and inexperienced directors

Envista Holdings Corporation (NYSE:NVST) completed the acquisition of Scanning Technology business of Carestream Dental LLC from Carestream Dental Parent Limited.

Envista Holdings Corporation to Report Q1, 2022 Results on May 04, 2022

Envista Holdings Corporation Announces Executive Changes

Envista Holdings Corporation Obtains FDA Clearance for Assisted Intelligence Mandibular Nerve Tracing

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Investor sentiment improved over the past week

Envista Holdings Corporation Receives FDA 510(k) Clearance for the Nobel Biocare N1™ Implant System

Envista Holdings Corporation (NYSE:NVST) entered into an agreement to acquire Scanning Technology business of Carestream Dental LLC for $600 million.

Third quarter 2021 earnings released: EPS US$0.50 (vs US$0.22 in 3Q 2020)

planmeca Verwaltungs GmbH entered into a binding agreement to acquire KaVo Dental Treatment Unit and Instrument Business for approximately $460 million.

Second quarter 2021 earnings released: EPS US$0.56 (vs US$0.59 loss in 2Q 2020)

First quarter 2021 earnings released: EPS US$0.45 (vs US$0.11 loss in 1Q 2020)

New 90-day high: €33.20

Insider recently sold €411k worth of stock

Envista Extends Partnership with Heartland Dental to Continue Providing Innovative Dental Solutions to Its Vast Network of Supported Doctors

Full year 2020 earnings released: EPS US$0.21 (vs US$1.60 in FY 2019)

Revenue beats expectations

New 90-day high: €31.80

Envista Holdings Corporation to Report Q4, 2020 Results on Feb 10, 2021

New 90-day high: €30.40

New 90-day high: €26.80

New 90-day high: €25.80

New 90-day high: €24.80

Third-quarter earnings released: Revenue beats expectations

Third quarter earnings released

Envista Holdings Corporation to Report Q3, 2020 Results on Oct 29, 2020

Envista Holdings Corporation Is Not Providing Guidance for 2020

New 90-day high - €20.80

Envista Holdings Corporation to Report Q2, 2020 Results on Jul 30, 2020

Envista Holdings Corporation(NYSE:NVST) dropped from Russell 2500 Growth Index

Envista Holdings Corporation(NYSE:NVST) dropped from Russell 3000 Growth Index

CEO

Permanencia

Equipo directivo

Permanencia media

Promedio de edad